Prospects of CD44 in hepatocellular carcinoma: An emerging biomarker and therapeutic target
Eurasian Journal of Medicine and Oncology · 07.10.2025 · 10 (5) · 025240260
DOI: 10.36922/ejmo025240260 ↗Kurz gefasst
Fachartikel in der Zeitschrift Eurasian Journal of Medicine and Oncology, online erschienen am 07.10.2025. Verfasst von Maomao Shu und 9 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
CD44, a single-transmembrane glycoprotein with diverse functional roles, has emerged as a critical regulator of tumor behavior, particularly in hepatocellular carcinoma (HCC). Elevated CD44 expression in HCC correlates with aggressive disease progression, positioning it as a promising diagnostic and prognostic biomarker. At the molecular level, CD44 orchestrates key oncogenic processes, including enhanced cellular proliferation, accelerated cell cycle progression, and increased migratory capacity, thereby driving HCC pathogenesis. As therapeutic strategies for HCC become more aggressive, invasive interventions are associated with adverse clinical outcomes, highlighting the need for targeted approaches. This review comprehensively analyzes current literature on CD44, addressing its structural diversity, isoform-specific functions, and signaling mechanisms in HCC. Furthermore, we discuss its prognostic significance, role in therapeutic resistance, and potential as a molecular target. By synthesizing these findings, this work aims to provide novel insights into early detection, accurate diagnosis, and the development of precision therapies for HCC, ultimately improving clinical outcomes.
Zitieren
APA
Shu, M., Qu, J., Luo, S., Xiao, T., Xiang, Z., Yan, L., Liu, J., Liu, Y., Lu, X., & Peng, X. (2025). Prospects of CD44 in hepatocellular carcinoma: An emerging biomarker and therapeutic target. Eurasian Journal of Medicine and Oncology, 10(5), 025240260. https://doi.org/10.36922/ejmo025240260
Vancouver
Shu M, Qu J, Luo S, Xiao T, Xiang Z, Yan L, et al. Prospects of CD44 in hepatocellular carcinoma: An emerging biomarker and therapeutic target. Eurasian Journal of Medicine and Oncology. 2025;10(5):025240260. doi:10.36922/ejmo025240260
BibTeX
@article{Shu2025,
author = {Shu, Maomao and Qu, Juan and Luo, Shunli and Xiao, Tao and Xiang, Ziye and Yan, Lingying and Liu, Jiaxing and Liu, Yujia and Lu, Xingjun and Peng, Xiaozhen},
title = {Prospects of CD44 in hepatocellular carcinoma: An emerging biomarker and therapeutic target},
journal = {Eurasian Journal of Medicine and Oncology},
year = {2025},
volume = {10},
number = {5},
pages = {025240260},
doi = {10.36922/ejmo025240260}
}
EUVIMED